KISSEI

  • Link
  • Japanese Page

Change Font Size

  • normal
  • large
  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations
  • Sustainability

About Kissei

Research & Development

News Release

Investor Relations

Sustainability

kissei

  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations
  • Sustainability
  • Link
  • Japanese Page
  • English
  • Message
  • Philosophy
  • Company Profile
  • Our Business
  • KISSEI's History
  • Corporate Governance
  • About R&D
  • Central Research Laboratories
  • Safety Research Laboratories
  • Joetsu Chemical Laboratories
  • Pharmaceutical Laboratories
  • R&D Pipeline
  • Business Results
  • Annual Report
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • CSR Management
  • SDGs
  • Materiality
  • Compliance
  • Social Contribution Activities
  • Environmental Initiatives
  • Consideration for Employees
  • ESG Data
  • Message
  • Philosophy
  • Company Profile
  • Our Business
  • KISSEI's History
  • Corporate Governance
  • About R&D
  • Central Research Laboratories
  • Safety Research Laboratories
  • Joetsu Chemical Laboratories
  • Pharmaceutical Laboratories
  • R&D Pipeline
  • Business Results
  • Annual Report
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • CSR Management
  • SDGs
  • Materiality
  • Compliance
  • Social Contribution Activities
  • Environmental Initiatives
  • Consideration for Employees
  • ESG Data
  • English Home
  • News Release

News Release

2022

  • April 27, 2022

    Submission of New Drug Application for Fostamatinib, an oral spleen tyrosine kinase inhibitor, in Japan

  • April 25, 2022

    Confirmation of Positive CHMP Opinion for GnRH Antagonist "Linzagolix" in Europe

  • April 22, 2022

    Kissei Announces New President and COO

  • March 31, 2022

    Results of Phase III Clinical Study of "CAROGRA® Tablets" Conducted in Japan for Treatment of Ulcerative Colitis (AJM300/CT3) Published in The Lancet Gastroenterology & Hepatology

  • March 28, 2022

    "CAROGRA® Tablets", Approved in Japan for Treatment of Ulcerative Colitis - The World-First Orally Available α4 Integrin Antagonist -

  • February 7, 2022

    Update on EU marketing authorisation process for "Linzagolix" for the reatment of uterine fibroids

  • January 7, 2022

    Positive Topline Results from Japanese Phase III Clinical Study (double-blind period) of Difelikefalin (MR13A9) in Hemodialysis Patients with Pruritus

  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations
  • Terms of Use
  • Privacy Policy
© 2012- Kissei Pharmaceutical Co., Ltd. All rights reserved.
キッセイ薬品工業株式会社

Thank you for visiting the Kissei website.
You are now moving to an external website.
(A new window will be opened.)

Access the link